| ||
Name: 5-{6-[(1-methylpiperidin-4-yl)oxy]-1h-benzimidazol-1-yl}-3-{[2-(trifluoromethyl)benzyl]oxy}thiophene-2-carboxamide | ||
Formula: C26 H25 F3 N4 O3 S | ||
Weight: 530.562 | ||
SMILES: "CN1CCC(CC1)Oc2ccc3ncn(c4sc(C(N)=O)c(OCc5ccccc5C(F)(F)F)c4)c3c2" | ||
Spacial conformation based on PDB 2xno |
RESIDUE ED8 62 CONECT C01 4 N02 H01 H01A H01B CONECT N02 3 C01 C03 C37 CONECT C03 4 N02 C04 H03 H03A CONECT C04 4 C03 C05 H04 H04A CONECT C05 4 C04 O06 C36 H05 CONECT O06 2 C05 C07 CONECT C07 3 O06 C08 C35 CONECT C08 3 C07 C09 H08 CONECT C09 3 C08 C10 H09 CONECT C10 3 C09 N11 C34 CONECT N11 2 C10 C12 CONECT C12 3 N11 N13 H12 CONECT N13 3 C12 C14 C34 CONECT C14 3 N13 C15 S33 CONECT C15 3 C14 C16 H15 CONECT C16 3 C15 O17 C29 CONECT O17 2 C16 C18 CONECT C18 4 O17 C19 H18 H18A CONECT C19 3 C18 C20 C24 CONECT C20 3 C19 C21 H20 CONECT C21 3 C20 C22 H21 CONECT C22 3 C21 C23 H22 CONECT C23 3 C22 C24 H23 CONECT C24 3 C19 C23 C25 CONECT C25 4 C24 F26 F27 F28 CONECT F26 1 C25 CONECT F27 1 C25 CONECT F28 1 C25 CONECT C29 3 C16 C30 S33 CONECT C30 3 C29 N31 O32 CONECT N31 3 C30 HN31 HN3A CONECT O32 1 C30 CONECT S33 2 C14 C29 CONECT C34 3 C10 N13 C35 CONECT C35 3 C07 C34 H35 CONECT C36 4 C05 C37 H36 H36A CONECT C37 4 N02 C36 H37 H37A CONECT H01 1 C01 CONECT H01A 1 C01 CONECT H01B 1 C01 CONECT H03 1 C03 CONECT H03A 1 C03 CONECT H04 1 C04 CONECT H04A 1 C04 CONECT H05 1 C05 CONECT H08 1 C08 CONECT H09 1 C09 CONECT H12 1 C12 CONECT H15 1 C15 CONECT H18 1 C18 CONECT H18A 1 C18 CONECT H20 1 C20 CONECT H21 1 C21 CONECT H22 1 C22 CONECT H23 1 C23 CONECT HN31 1 N31 CONECT HN3A 1 N31 CONECT H35 1 C35 CONECT H36 1 C36 CONECT H36A 1 C36 CONECT H37 1 C37 CONECT H37A 1 C37 END HET ED8 62 HETNAM ED8 5-{6-[(1-methylpiperidin-4-yl)oxy]-1H-benzimidazol-1-yl HETNAM 2 ED8 }-3-{[2-(trifluoromethyl)benzyl]oxy}thiophene-2-carboxa HETNAM 3 ED8 mide FORMUL ED8 C26 H25 F3 N4 O3 S1
This OCA
MONOMER page uses Jmol, developed by the Jmol Development Team (color reference)
|